Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1994 Sep:62 Suppl 1:16-8.

[Paroxetine in the treatment of depression in geriatric patients--a double-blind comparative study with fluoxetine]

[Article in German]
Affiliations
  • PMID: 7959520
Clinical Trial

[Paroxetine in the treatment of depression in geriatric patients--a double-blind comparative study with fluoxetine]

[Article in German]
W Schöne et al. Fortschr Neurol Psychiatr. 1994 Sep.

Abstract

A 6-week double-blind, parallel group study compared paroxetine and fluoxetine in 106 depressed geriatric inpatients (aged 65 to 85 years). Patients presenting acutely with major depressive episode DSM-III-R 296.2 (HAMD > 18 on 21 item scale) were randomized to receive paroxetine (20-40 mg, n = 54) or fluoxetine (20-60 mg, n = 52) following a 3-7 day washout. Primary criteria was the reduction of Hamilton Depression Rating Scale Score (HAMD). Furthermore Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression Scale (CGI) were used. Cognitive functions were assessed with the Mini-Mental-State Examination (MMSE) and the Sandoz Clinical Assessment Geriatric Scale (SCAG). The results showed a comparable reduction in the depression rating scales between the two treatment groups after 6 weeks. However, there was a statistically significant difference (p < 0.05) in HAMD, MADRS, SCAG, MMSE and cognitive subscales of HAMD and SCAG at week 3 in favour of paroxetine, which even was seen after 6 weeks in the SCAG. There were no significant differences between the treatment groups and the number of adverse events reported or in overall tolerability.

PubMed Disclaimer